EGFR and non-small cell lung carcinoma: Furthermore, we confirmed that the EGFR TKI, afatinib, significantly suppressed the expression of CypA and CD147 in EGFR-mutant NSCLC CSCs, suggesting that there may be close crosstalk between the CypA/CD147 and EGFR pathways in maintaining the stem-like properties of NSCLC.